sorivudine
Sorivudine (INN), is a nucleoside analogue antiviral drug, marketed under trade names such as Usevir and Brovavir (BMS). It is used for the treatment of varicella zoster virus infections. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Nov 2, 1999 (NCT00000953)
Timeline
Indications
Mechanism of action
- DNA polymerase catalytic subunitINHIBITOR
DNA polymerase catalytic subunit inhibitor
It derives its antiviral activity from selective conversion by a specific thymidine kinase, present in certain DNA viruses, to nucleotides which in turn interfere with viral DNA synthesis. This viral thymidine kinase is different from the thymidine kinase present in mammalian cells. Sorivudine isnot a substrate for mammalian thymidine kinase, thus explaining the selectivity of this drug.
Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, Epstein-Barr virus.
- DNA polymeraseINHIBITOR
DNA polymerase inhibitor
It derives its antiviral activity from selective conversion by a specific thymidine kinase, present in certain DNA viruses, to nucleotides which in turn interfere with viral DNA synthesis. This viral thymidine kinase is different from the thymidine kinase present in mammalian cells. Sorivudine isnot a substrate for mammalian thymidine kinase, thus explaining the selectivity of this drug.
Sorivudine has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, Epstein-Barr virus.
Chemistry & pharmacology
SMILES
O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)cc1/C=C/Br- Mol. weight
- 349.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSorivudine ↗
- ChEMBLCHEMBL70046 ↗
Also known as
- 1-beta-d-arabinofuranosyl-5-(2-bromovinyl)uracil
- 1-beta-d-arabinofuranosyl-e-5-(2-bromovinyl)uracil
- 2,4(1h,3h)-pyrimidinedione, 1-beta-d-arabinofuranosyl-5-(2-bromoethenyl)-, (e)-
- 5-(2-bromovinyl)-1-beta-d-arabinofuranosyluracil
- bravavir
- bravavir
- bravavir
- brovavir
- brovavir
- brovavir
- brovavir
- bv-arau
- bv-arau
- bv-arau
- bv-ara-u
- so-32756
- so-32756
- sorivudine
- sorivudine
- sorivudine
- sorivudine
- sorivudine
- sorivudine
- sorivudine
- sorivudine
- sorivudine
- yn-72
- yn-72
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00652184 | Phase 2 | Mar 1, 2008 | aRigen Pharmaceuticals, Inc. |
| NCT00000953 | Phase 2 | Nov 2, 1999 | Bristol-Myers Squibb, Glaxo Wellcome, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002358 | Phase 3 | Nov 2, 1999 | Bristol-Myers Squibb |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 1 | 2 | 1999 |
| aRigen Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2008 |
| Glaxo Wellcome | For profit | 1 | 0 | 1 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |